LGND Ligand Pharmaceuticals (LGND) Q4 FY25 earnings call
Ligand Pharmaceuticals concluded a defining FY25 with exceptional financial performance, driven by robust royalty growth from its diversified portfolio and strategic operational changes. The company reaffirmed its 2026 financial guidance, anticipating continued momentum from key commercial products and an accelerating business development pipeline, supported by a strong capital base. Management highlighted significant progress in late-stage development assets, particularly positive Phase 3 data for QTORIN rapamycin and the successful re-partnering of lasofoxifene.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.